The Form 4 filing, an SEC report of insider stock activity, was filed on November 12, 2026. It lists November 9 as the earliest transaction date and November 11 as the latest. Richard Daniell serves as Teva's executive vice president for Europe Commercial.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 45,003 |
| Price | $42.86 |
| Total Transaction Value | $1,928,944.40 |
| Insider | |
| Ticker Symbol | TEVA |
| Company | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Insider Name | Daniell Richard |
| Insider Title | EVP, Europe Commercial |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 55,755 |
| Position Size Change | 44.66% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were two share sales, reported under SEC transaction code S. The available details also suggest a link to an exercise or conversion, a step that turns a stock right or another security into shares.
What was the average price of the transaction?
The average sale price was $42.86 per share across the two transactions, rounded to the nearest cent.
How did this transaction affect the insider's holdings?
The 45,003 shares sold represented 44.66% of Richard Daniell's reported shares before the sales. He reported owning 55,755 shares afterward.
What's the total transaction value?
The two transactions had a total sale value of $1,928,944.40, rounded to cents.
Are there any special circumstances around this transaction?
Yes. The sales have a reported link to an exercise or conversion. That link comes from matching an acquisition under code M with a sale under code S for the same share count in this filing.
The separate acquisition entry and filing footnotes are unavailable here. Whether the entries share the same date, type of shares or account remains unknown. The match also leaves unclear whether the acquired shares were the ones sold.
For research purposes only; not investment advice.